Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Amgen’s Immuno-Oncology Strategy Hinges On T-VEC’s Mechanism, Combinability

This article was originally published in The Pink Sheet Daily

Executive Summary

Awaiting FDA approval for monotherapy in metastatic melanoma, Amgen uses ASCO to launch new combination studies with Merck and Roche immune checkpoint inhibitors, adding to one ongoing with Bristol’s Yervoy.



Related Companies